Parastoo Taheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Parastoo Taheri has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Esmaeil Farmani Gheshlaghi
2 shared publications- Hamed Aghazadeh
Department of Therapeutic Dentistry and Prosthodontics, Azerbaijan Medical University, Baku, Azerbaijan
2 shared publications Manijeh Motevalian
Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publicationsBehnaz Hazrati Dorigh
1 shared publicationElaheh Shahmoradi
Department of Chemistry, Faculty of Sciences, University of Zanjan 45371-38791, Zanjan, Iran
1 shared publicationHossein Ghaffari
Young Researchers and Elites Club, Islamic Azad University of Tabriz Branch, Tabriz, Iran
1 shared publication
Latest Publications
- 1 July 2022
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 169 (7) , 077517
Design and Production of DNA-Based Electrochemical and Biological Biosensors for the Detection and Measurement of Gabapentin Medication in Clinical Specimens
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient’s bloodstream, thereby optimizing individual dosage regimens. Hence, the extant study was conducted to design and produce an electrochemical and biological biosensor to detect and measure Gabapentin medication. The present study was a laboratory-applied intervention, which used a pencil graphite electrode modified with α -Fe 2 O 3 and MOS 2 nanostructures in one step and DNA in the second address layer, by using Differential Pulse Voltammetry (DPV) electrochemical sensing techniques to detect Gabapentin medication in clinical specimens such as serum, plasma, and urine. The functional mechanism of the biosensor is designed in such a way that the effect of interaction between drug and DNA leads to drug detection, and with increasing concentration of Gabapentin analyte, the amount of visible current by DNA is reduced. Significantly, this reduction in current after reaction with Gabapentin can be demonstrated using the Differential Pulse Voltammogram (DPV) curve. The designed biosensor provided some features, including inexpensiveness, simple and fast sensor biodegradation process, appropriate stability of sensor, low Limit of Detection (LOD), extensive linearity range, ease of application without requiring laboratory technician, and selectivity of biosensor materials. Electrochemical and biological biosensors have some advantages rather than the common analytical methods; hence, these biosensors can be used widely in the future. High selectivity, low cost of production and low energy consumption, accuracy and precision, short response time, adaptability, simple preparedness, minimization capability, high-speed data collecting, low LOD, minor operational volume, and robust measurement. On the other hand, biosensors have received great attention over recent years due to their continuous application, the high selectivity of biological compounds, such as enzymes and antibodies, and the ability to measure nonpolar compounds.
- 1 July 2022
- Published by The Electrochemical Society in Journal of the Electrochemical Society
- Vol. 169 (7) , 077517
Design and Production of DNA-Based Electrochemical and Biological Biosensors for the Detection and Measurement of Gabapentin Medication in Clinical Specimens
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient’s bloodstream, thereby optimizing individual dosage regimens. Hence, the extant study was conducted to design and produce an electrochemical and biological biosensor to detect and measure Gabapentin medication. The present study was a laboratory-applied intervention, which used a pencil graphite electrode modified with α -Fe 2 O 3 and MOS 2 nanostructures in one step and DNA in the second address layer, by using Differential Pulse Voltammetry (DPV) electrochemical sensing techniques to detect Gabapentin medication in clinical specimens such as serum, plasma, and urine. The functional mechanism of the biosensor is designed in such a way that the effect of interaction between drug and DNA leads to drug detection, and with increasing concentration of Gabapentin analyte, the amount of visible current by DNA is reduced. Significantly, this reduction in current after reaction with Gabapentin can be demonstrated using the Differential Pulse Voltammogram (DPV) curve. The designed biosensor provided some features, including inexpensiveness, simple and fast sensor biodegradation process, appropriate stability of sensor, low Limit of Detection (LOD), extensive linearity range, ease of application without requiring laboratory technician, and selectivity of biosensor materials. Electrochemical and biological biosensors have some advantages rather than the common analytical methods; hence, these biosensors can be used widely in the future. High selectivity, low cost of production and low energy consumption, accuracy and precision, short response time, adaptability, simple preparedness, minimization capability, high-speed data collecting, low LOD, minor operational volume, and robust measurement. On the other hand, biosensors have received great attention over recent years due to their continuous application, the high selectivity of biological compounds, such as enzymes and antibodies, and the ability to measure nonpolar compounds.
- Open Access
- 1 January 2019
- Published by Wolters Kluwer Health in International Journal of Preventive Medicine
- Vol. 10 (1) , 195
Preventive Effects of Duloxetine Against Methamphetamine Induced Neurodegeneration and Motor Activity Disorder in Rat: Possible Role of CREB/BDNF Signaling Pathway
Background: The neuroprotective effects of duloxetine and neurodegenerative effects of methamphetamine have been shown in previous studies, but their exact mechanism remain unclear. In the current study it involved molecular mechanisms of neuroprotective effects of duloxetine against methamphetamine induced neurodegeneration were clarified. Methods: About 40 adult male rats randomly were divided to 5 groups. Group 1 and 2, as control and methamphetamine treated, received normal saline and methamphetamine (10 mg/kg) respectively. Groups 3, 4 and 5 concurrently treated with methamphetamine and duloxetine at doses of 10, 20 and 30 mg/kg respectively. All treatments were undertaken for 21 days. On day 22 Open Field Test (OFT) were used to examine the level of motor activity disturbance and anxiety in animals. After that hippocampus was isolated from each rat and oxidative, antioxidant, inflammatory factors and also level or expression of total and phosphorylated forms of CREB and P-CREB and BDNF proteins were measured. Results: Duloxetine in all mentioned doses could inhibit the effects of methamphetamine induced motor activity disturbance in MWM. Chronic abuse of methamphetamine could increase malondialdehyde (MDA), tumor necrosis factor-Alpha (TNF-α) and interleukine-1beta (IL-1β) while caused decreases in superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activities and decreased CREB (both forms) and BDNF proteins, while duloxetine could prevent these malicious effects of methamphetamine. Conclusions: We conclude that P-CREB/BDNF signaling pathways might have critical role in duloxetine neuroprotective effects against methamphetamine induced neurodegeneration.
- 1 January 2019
- Published by Wolters Kluwer Health in International Journal of Preventive Medicine
- Vol. 10 (1) , 195
Open AccessPreventive Effects of Duloxetine Against Methamphetamine Induced Neurodegeneration and Motor Activity Disorder in Rat: Possible Role of CREB/BDNF Signaling Pathway
Background: The neuroprotective effects of duloxetine and neurodegenerative effects of methamphetamine have been shown in previous studies, but their exact mechanism remain unclear. In the current study it involved molecular mechanisms of neuroprotective effects of duloxetine against methamphetamine induced neurodegeneration were clarified. Methods: About 40 adult male rats randomly were divided to 5 groups. Group 1 and 2, as control and methamphetamine treated, received normal saline and methamphetamine (10 mg/kg) respectively. Groups 3, 4 and 5 concurrently treated with methamphetamine and duloxetine at doses of 10, 20 and 30 mg/kg respectively. All treatments were undertaken for 21 days. On day 22 Open Field Test (OFT) were used to examine the level of motor activity disturbance and anxiety in animals. After that hippocampus was isolated from each rat and oxidative, antioxidant, inflammatory factors and also level or expression of total and phosphorylated forms of CREB and P-CREB and BDNF proteins were measured. Results: Duloxetine in all mentioned doses could inhibit the effects of methamphetamine induced motor activity disturbance in MWM. Chronic abuse of methamphetamine could increase malondialdehyde (MDA), tumor necrosis factor-Alpha (TNF-α) and interleukine-1beta (IL-1β) while caused decreases in superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activities and decreased CREB (both forms) and BDNF proteins, while duloxetine could prevent these malicious effects of methamphetamine. Conclusions: We conclude that P-CREB/BDNF signaling pathways might have critical role in duloxetine neuroprotective effects against methamphetamine induced neurodegeneration.
- Open Access
- 1 January 2018
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 7 (1) , 151
Neuroprotective Effects of Forced Exercise and Bupropion on Chronic Methamphetamine-induced Cognitive Impairment via Modulation of cAMP Response Element-binding Protein/Brain-derived Neurotrophic Factor Signaling Pathway, Oxidative Stress, and Inflammatory Biomarkers in Rats
Background: Forced exercise can act as non-pharmacologic neuroprotective agent. In current study, we tried the involved molecular mechanisms of protective effects of forced exercise against methamphetamine induced neurodegeneration. Materials and Methods: Forty adult male rats were divided to Group 1 and 2 which received normal saline and methamphetamine (10 mg/kg) respectively for 30 days. Groups 3, 4 and 5 were treated with methamphetamine for first 15 days and then were treated by forced exercise, bupropion (20 mg/kg/day) or combination of them for the following 15 days. Between 26th and 30th days, Morris Water Maze (MWM) was used to evaluate the cognition. On day 31, hippocampus was isolated from each rat and oxidative, antioxidant and inflammatory factors also the level of total and phosphorylated forms of cAMP response element-binding protein (CREB) and brain derived neurotrophic factor (BDNF) proteins were also evaluated. Results: Chronic abuse of methamphetamine could decreases cognition and increase malondialdehyde (MDA), Tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), while caused decreases in superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activities all these changes was significant (P < 0.001) in compared to control group while treatment with bupropion, forced exercise and bupropion in combination with forced exercise could prevent all these malicious effects of methamphetamine (P < 0.001). Bupropion, forced exercise and bupropion in combination with forced exercise could activate CREB (both forms) and activates BDNF proteins’ expression with P < 0.001 in methamphetamine treated rats. Conclusions: P-CREB/BDNF signaling pathways might have critical role in forced exercise protective effects against methamphetamine induced neurodegeneration.
- 1 January 2018
- Published by Wolters Kluwer Health in Advanced Biomedical Research
- Vol. 7 (1) , 151
Open AccessNeuroprotective Effects of Forced Exercise and Bupropion on Chronic Methamphetamine-induced Cognitive Impairment via Modulation of cAMP Response Element-binding Protein/Brain-derived Neurotrophic Factor Signaling Pathway, Oxidative Stress, and Inflammatory Biomarkers in Rats
Background: Forced exercise can act as non-pharmacologic neuroprotective agent. In current study, we tried the involved molecular mechanisms of protective effects of forced exercise against methamphetamine induced neurodegeneration. Materials and Methods: Forty adult male rats were divided to Group 1 and 2 which received normal saline and methamphetamine (10 mg/kg) respectively for 30 days. Groups 3, 4 and 5 were treated with methamphetamine for first 15 days and then were treated by forced exercise, bupropion (20 mg/kg/day) or combination of them for the following 15 days. Between 26th and 30th days, Morris Water Maze (MWM) was used to evaluate the cognition. On day 31, hippocampus was isolated from each rat and oxidative, antioxidant and inflammatory factors also the level of total and phosphorylated forms of cAMP response element-binding protein (CREB) and brain derived neurotrophic factor (BDNF) proteins were also evaluated. Results: Chronic abuse of methamphetamine could decreases cognition and increase malondialdehyde (MDA), Tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), while caused decreases in superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activities all these changes was significant (P < 0.001) in compared to control group while treatment with bupropion, forced exercise and bupropion in combination with forced exercise could prevent all these malicious effects of methamphetamine (P < 0.001). Bupropion, forced exercise and bupropion in combination with forced exercise could activate CREB (both forms) and activates BDNF proteins’ expression with P < 0.001 in methamphetamine treated rats. Conclusions: P-CREB/BDNF signaling pathways might have critical role in forced exercise protective effects against methamphetamine induced neurodegeneration.